Thymogen — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Thymogen

Also known as: L-Glu-L-Trp, Glu-Trp, EW dipeptide, IM862 (related dipeptide; see notes)

Synthetic thymic immunomodulatory dipeptide (thymomimetic)

Research chemicalLast updated: October 19, 2026Based on 15 peer-reviewed studies

What it is

Thymogen is a synthetic thymic dipeptide studied for its immune-stimulating and antioxidant properties, with potential applications in liver protection and immune deficiency. It works by activating key immune cells to strengthen the body's defense responses. No FDA-approved use; primarily studied in Russian research with limited independent replication.

The scientific side

Thymogen (L-Glu-L-Trp) is a dipeptide originally isolated from thymus homogenate with immunostimulatory properties. Published studies indicate it binds with high affinity to murine peritoneal macrophages and thymocytes (inhibiting binding of the related dipeptide bestim), and is characterised as an immunostimulant in contrast to its D-enantiomer-based counterpart Thymodepressin, which is immunosuppressive — illustrating reciprocal biological activity based on chirality. It has been described as a modulator of cellular immunity, a thymomimetic, and an interferon inducer in the reviewed literature. The glutamic acid–tryptophan scaffold has also been shown to inhibit angiotensin-converting enzyme (ACE) activity in endothelial cells and to block angiotensin I-induced vasoconstriction ex vivo and in vivo, though this ACE-inhibitory work was conducted primarily with the EW peptide in a comparative context. Thymogen analogues have demonstrated antioxidant and hepatoprotective effects in animal models of toxic liver injury.

Class: Synthetic thymic immunomodulatory dipeptide (thymomimetic)

Administration & storage

Administration
Intranasal instillation (PMID: 21957588)Intranasal daily administration (PMID: 17879948)Intragastric administration in animal model (PMID: 37861903)In vitro cell culture incubation (PMID: 35408963PMID: 18365736PMID: 18428206)
Storage
No storage conditions for Thymogen are described in the reviewed abstracts.
Cautions
Human safety data are limited to a small number of clinical studies; no significant toxicities were reported in the IM862 intranasal RCT and immunomodulatory therapy was well tolerated in the pre-surgical elderly cohort, but long-term safety data are not available from the reviewed literature.,Thymogen is highly hydrophilic with low membrane permeability in its native form, which limits oral bioavailability; novel conjugates designed to improve absorption have not yet been clinically validated.,The peptide's biological activity is highly dependent on stereochemistry — the D-enantiomer-based Thymodepressin has immunosuppressive rather than immunostimulatory effects, underscoring the importance of confirmed peptide identity and purity in any preparation.,No clinical pharmacokinetic or pharmacodynamic data in humans are reported in the reviewed abstracts.,Sterile technique should be observed for any injectable or intranasal preparation to prevent contamination.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification